TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of moderate to severe stable Chronic Obstructive Pulmonary Disease (COPD) stage II or stage III according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines (2009)~* Qualifying spirometry, Forced Expiratory Volume in one second (FEV1) and post-bronchodilator FEV1/FVC (Forced Vital capacity)~* Smoking history ≥ 10 pack years~Exclusion Criteria:~* Pregnant women or nursing mothers or women of child-bearing potential not using adequate contraception~* Cardiac abnormality~* History of asthma~* Contraindications to cardiopulmonary exercise testing~* Participation in active phase of pulmonary rehabilitation program~* History of cancer within the past 5 years~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- indacaterol and glycopyrronium bromide (QVA149) (Type: EXPERIMENTAL): QVA149 delivered once daily via single-dose dry powder inhaler.
- placebo (Type: PLACEBO_COMPARATOR): Placebo, delivered once daily via single-dose dry powder inhaler.
- tiotropium (Type: ACTIVE_COMPARATOR): Tiotropium delivered once daily via HandiHaler® device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of XueZhiKang on Fatigue：Comparing With Simvastatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. LDL cholesterol level between 115-190 mg/dL;~2. Able to fast prior to blood draw;~3. Able to comfortably read and write in Chinese;~4. Able and willing to refrain from donating whole blood during study participation;~5. Willing to abstain from consuming large amounts of grapefruit juice.~Exclusion Criteria:~1. Current use of lipid-lowering medications;~2. Documented cardiovascular disease (CVD) by invasive or non-invasive testing (such as coronary angiography, nuclear imaging, stress echocardiography, carotid plaque on ultrasound), previous myocardial infarction (MI), acute coronary syndrome (ACS), coronary revascularization \[percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG)\] and other arterial revascularization procedures, ischaemic stroke, peripheral arterial disease(PAD);~3. Patients with type 2 diabetes, patients with type 1 diabetes with target organ damage (such as microalbuminuria);~4. Patients with moderate to severe chronic kidney disease \[glomerular filtration rate (GFR) \< 60 mL/min/1.73㎡\];~5. Markedly elevated single risk factors such as familial dyslipidaemias and severe hypertension;~6. A calculated SCORE ≥5% for 10 year risk of fatal CVD;~7. Cancer;~8. HIV infected;~9. Medical or psychiatric condition that prevents full study participation or follow-up (e.g., active psychosis);~10. Active liver disease or unexplained persistent elevated transaminase levels；~11. Major surgery or hospitalization in the 3 months prior to study entry;~12. Current use of cyclosporin, erythromycin, clarithromycin, nefazodone, or any azole antifungals, including fluconazole, itraconazole, ketoconazole, mibefradil, or protease inhibitors;~13. Female of childbearing potential;~14. Current participation in another clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- XueZhiKang (Type: EXPERIMENTAL): Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
- Simvastatin (Type: ACTIVE_COMPARATOR): Participants will receive 20mg of simvastatin daily for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of CDB-2914 Versus Placebo in the Prevention of Follicular Rupture Post-luteinizing Hormone (LH) Surge

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women of good general health aged 18 - 35 years~* Not at risk of pregnancy~* Regular menstrual cycles of 24-35 days duration~* Not pregnant~* Intact uterus and ovaries~* Haemoglobin ≥ 11 g/dl~* Normal laboratory tests and normal TSH~* Willing to abstain from any use of hormonal contraception until study completion~* No current use of hormonal contraception and having had at least one complete menstrual cycle (2 menses) since termination of previous hormonal contraception~* Had at least one complete menstrual cycle (2 menses) following delivery, miscarriage or induced abortion~* Able to give voluntary, written informed consent, and agreeing to observe all study requirements for 5 complete menstrual cycles~Exclusion Criteria:~* Current participation in any other trial of an investigational medicine~* Known hypersensitivity to the ingredients of the test active substances or excipients~* Suspected hyperplasia or carcinoma of the endometrium~* Current pregnancy as confirmed by positive serum beta-hCG at screening~* Desire to get pregnant before the planned end of the study participation~* Currently breastfeeding~* Abnormal Pap smear~* Cancer (past history of any carcinoma or sarcoma)~* Known or suspected alcoholism or drug abuse~* Abnormal thyroid status~* Body mass index \> 32~* Current use of hormonal contraception~* Use of hormonal emergency contraception since last menstrual period~* Severe asthma insufficiently controlled by oral glucocorticoids~* Hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- CDB-2914 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject who is free of obvious health problems~* Able and willing to comply with the study procedure adn give written informed consent~Exclusion Criteria:~* Female who is pregnant/lactating or planning to be pregnant~* Body mass index(BMI) \> 35~* Oral temperature \> 37.5 Celsius at the time of planned vaccination~* Subject with any abnormal laboratory results at screening~* With a history of herpangina, hand-foot-mouth disease, acute hemorrhagic conjunctivitis or acute gastrointestinal illness associated with enterovirus infection in the past 3 months~* Has been diagnosed with neurological, pulmonary, cardiovascular, hematological, hepatic or renal disorder~* With a history of hypersensitivity to vaccine or allergic disease~* Use of any investigational/non-registered product within 30 days prior to vaccination~* Use of immunoglobulins or any blood products within 3 months prior to vaccination~* Chronic administration of immunosuppressants or other immunomodulators within 5 months prior to vaccination

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- EV 71 vaccine 5ug (Type: ACTIVE_COMPARATOR): EV71 Vaccine 5ug
- EV 71 vaccine 10ug (Type: EXPERIMENTAL): EV71 vaccine 10ug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of An Innovative Smartphone Intervention for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 or older~* smokes at least five cigarettes daily for at least past 12 months~* wants to quit cigarette smoking in the next 30 days~* if concurrently using any other nicotine or tobacco products, wants to quit using them within the next 30 days~* interested in learning skills to quit smoking~* willing to be randomly assigned to either condition~* resides in US~* has at least daily access to their own personal Apple iPhone, Android, or Windows Phone~* knows how to login and download a smartphone application~* willing and able to read in English~* not using other smoking cessation interventions (including apps or our other intervention studies).~* willing to complete all three follow-up surveys~* provide email, phone, and mailing address.~Exclusion Criteria:~* The exclusion criteria are opposite of the inclusion criteria listed above.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Experimental (Type: EXPERIMENTAL): This is the experimental arm of the study. This includes receiving the novel/experimental smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study.
- Control (Type: ACTIVE_COMPARATOR): This is the control arm of the study. This includes receiving the standard of care smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and Cetuximab in Patients With Advanced or Metastatic Biliary Tract Cancer: A Multicenter Phase II Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histologically or cytologically proven locally advanced or metastatic unresectable adenocarcinoma of the biliary tract~* signed written informed consent~* age \> 18~* WHO PS 0 or 1 at study entry~* measurable (diameter ³ 1 cm) / evaluable disease, according to RECIST criteria~* adequate renal (serum creatinin\<1.5x upper reference range), liver (total bilirubin\<2x upper reference range) and hematopoietic functions (PMN\>1,5x109/L, platelets\>100x109/L)~* life expectancy of at least 12 weeks~* effective contraception throughout the study for both male and female patients if the risk of conception exists~Exclusion Criteria:~* uncontrolled concurrent CNS, cardiac, infectious diseases~* previous exposure to epidermal growth factor targeting therapy~* known hypersensitivity to any components of study treatments~* previous chemotherapy for this cancer~* previous malignancy in the last past 5 years except basal cell cancer of the skin or preinvasive cancer of the cervix~* pregnancy or breast feeding~* medical or psychological conditions that would not permit the patient to complete the study or sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): gemcitabine+cetuximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: StrataGraft® Skin Tissue Expanded Access at Specific Study Sites ( StrataCAT )

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~To be considered for inclusion, a participant must:~* Provide written informed consent~* Have enough healthy skin to reserve as donor site(s), in case autografting becomes necessary~* Have protocol-defined thermal burn(s) on the torso, upper extremities and lower extremities:~  1. that are the right size for treatment areas,~ 2. with intact dermal elements for which excision and autografting are clinically indicated, and~ 3. have not been previously excised and grafted.~Exclusion Criteria:~A participant must be excluded from participation if he/she:~* Is pregnant, a prisoner, or expected to live less than 3 months~* Has any other condition that, per protocol or in the opinion of the investigator, may compromise the participant's safety or the study objectives~* Has participated in an investigational study within 90 days before enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- StrataGraft (Type: EXPERIMENTAL): On Day 1, participants received a single application of up to 1:1 meshed StrataGraft skin tissue on up to 3 DPT wound(s) totaling no more than approximately 2000 square centimeters (cm\^2) in area.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine for Postoperative Pain of Laparoscopic Cholecystectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Patients who are scheduled to undergo elective LC~Exclusion Criteria:~1- Patients with acute pancreatitis 2. Patients undergoing chronic pain treatment 3. Patients who received analgesics or sedatives 24 h before scheduled surgery 3. Patients had alcohol or drug addiction 4. Severe hepatic and renal dysfunction 5. Previous allergic response to duloxetine 6. Pregnancy and lactation 7. Patients with communication problems, cognitive dysfunction, or psychological disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: ACTIVE_COMPARATOR): patients scheduled for elective LC will receive 60 mg duloxetine before surgery
- Control (Type: PLACEBO_COMPARATOR): patients scheduled for elective LC will receive placebo before surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Misoprostol for Cervical Priming Prior to Vacuum Aspiration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* women opting for first trimester surgical abortion~* nulliparous~* able and willing to provide informed consent~Exclusion Criteria:~* unwilling to participate,~* unable to communicate in Swedish and English and~* minors (i.e. women \< 18 years of age),~* contraindications to misoprostol~* women with pathological pregnancies

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Misoprostol sublingual,1h (Type: ACTIVE_COMPARATOR): Administration of misoprostol sublingually 1h prior to surgery
- Misoprostol sublingual. 3h (Type: ACTIVE_COMPARATOR): Administration of misoprostol sublingually 3h prior to surgery
- Misoprostol vaginal,1h (Type: ACTIVE_COMPARATOR): Administration of misoprostol vaginally 1h prior to surgery
- Misoprostol vaginal,3h (Type: ACTIVE_COMPARATOR): Administration of misoprostol vaginally 3h prior to surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Effectiveness of Combined NRT With Single NRT in Primary Care Clinics in Hong Kong

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* current smokers who smoke 10 or more cigarettes a day for at least one year~Exclusion Criteria:~* unstable angina~* severe cardiac arrhythmia~* recent acute myocardial infarction or cerebrovascular accident in preceding 3 months~* below 18 years old~* being pregnant or on breast-feeding~* unable to use gum~* with a previous history of failure to NRT~* with a history of hypersensitivity to nicotine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Usual group (Type: ACTIVE_COMPARATOR): Usual group with nicotine patch only:~Usual care involved counseling and 8 weeks of single NRT of nicotine patch. For those smoking 20 or more cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 21mg patches, then 2 weeks of 14mg patches, followed by 2 weeks of 7mg patches. For those smoking 10 to 19 cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 14mg patches, followed by 4 weeks of 7mg patches.
- Intervention group (Type: ACTIVE_COMPARATOR): Nicotine patch and nicotine gum:~Intervention consisted of counseling and 8 weeks of combined NRT of nicotine patch and gum. For those smoking 20 or more cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 21mg patches, then 2 weeks of 14mg patches, followed by 2 weeks of 7mg patches. For those smoking 10 to 19 cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 14mg patches, followed by 4 weeks of 7mg patches. 2mg nicotine gum was used once every 1 to 2 hours when required.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* primary renal transplant (not HLA identical)~* ages 18-60 years~Exclusion Criteria:~* recipient panel reactive antibody level \>10%~* recipient of a DCD kidney~* no prior organ transplant~* no multi-organ transplant recipient~* no subject who is currently receiving systemic corticosteroids~* no pregnant or lactating subjects~* no history of Hepatitis B, C or HIV positivity~* no recipient of a kidney with cold ischemia time \>36 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Campath 1H induction w/ Sirolimus immunosuppression (Type: EXPERIMENTAL): Campath 1H at day -1 and 0 of kidney transplant followed by long term CNI free immunosuppressive therapy with Sirolimus,

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Ability to provide written/verbal informed consent in accordance with GCP (Good Clinical Practice) and local legislation~2. Patients aged 18 \~ under 80~3. Hypertension as described below:~   * Newly diagnosed patients with hypertension~  * Patients with current antihypertensive therapy~Exclusion Criteria:~1. Female subjects who are breastfeeding, pregnant or who plan to be pregnant during the study~2. Known or suspected secondary hypertension(e.g. pheochromocytoma)~3. Patients who have been treated with telmisartan prior to the acquisition of informed consent (including verbal informed consent)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extended Dosing With Eltrombopag for Severe Aplastic Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Previous diagnosis of refractory severe aplastic anemia and following at least one treatment course of immunosuppression with a regimen containing antithymocyte globulin, alemtuzumab or cyclophosphamide.~* One or more of the following three clinically-significant cytopenias: platelet count less than or equal to 30,000/micro L or platelet-transfusion-dependence (requiring at least 4 platelet transfusions in the 8 weeks prior to study entry); neutrophil count less than 500/micro L; hemoglobin less than 9.0 g/dL or red cell transfusion-dependence (requiring at least 4 units of PRBCs in the eight weeks prior to study entry)~* Age greater than or equal to 2 years old~* Weight \> 12 kg~EXCLUSION CRITERIA:~* Infection not adequately responding to appropriate therapy~* Evidence of a clonal disorder on cytogenetics performed within 12 weeks of study entry.~* Creatinine \> 2.5 mg/dL~* Direct Bilirubin \> 2.0 mg/dL~* SGOT or SGPT \>5 times the upper limit of normal~* Hypersensitivity to eltrombopag or its components\<TAB\>~* Female subjects who are nursing or pregnant or are unwilling to take oral contraceptives or refrain from pregnancy if of childbearing potential~* Unable to understand the investigational nature of the study or give informed consent~* Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient s ability to tolerate protocol therapy, or that death within 7-10 days is likely~* Treatment with ATG, cyclophophamide or alemtuzamab within 6 months of study entry.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Eltrombopag (Type: EXPERIMENTAL): Administration of eltrombopag at a dose of 150mg/day for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete